856
Participants
Start Date
December 20, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Impella ECP
Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
CUMC/ New York Presbyterian Hospital, New York
Lenox Hill Hospital, New York
Buffalo General, Buffalo
Sentara Norfolk Health System, Norfolk
West Virginia University Hospital, Morgantown
Emory University Hospital, Atlanta
AdventHealth - Tampa, Tampa
Manatee Memorial Hospital, Bradenton
North Florida Regional Medical Center, Gainesville
TriStar Centennial Medical Center, Nashville
Henry Ford Hospital, Detroit
Ascension St. John Hospital, Detroit
Spectrum Health, Grand Rapids
St. Cloud (CentraCare), Saint Cloud
Providence St. Patrick, Missoula
Ochsner Foundation Hospital, New Orleans
Arkansas Heart Hospital, Little Rock
Oklahoma Heart Hospital - South, Oklahoma City
Baylor Scott & White The Heart Hospital Plano, Plano
Texas Health Presbyterian Hospital Dallas, Dallas
Methodist Hospital - San Antonio, San Antonio
St. Joseph's Medical Center - Phoenix, Phoenix
Pima Heart & Vascular, Tucson
New Mexico Heart Institute, Albuquerque
Keck Hospital of USC, Los Angeles
Adventist Health Glendale, Glendale
Loma Linda University Medical Center, San Bernardino
Providence St. Vincent Med Center, Portland
Tufts Medical Center, Boston
Hackensack University Medical Ctr, Hackensack
Morristown Medical Center, Morristown
The Valley Hospital, Ridgewood
Lead Sponsor
Abiomed Inc.
INDUSTRY